Article

CRISPR screening identifies novel PARP inhibitor classification based on distinct base excision repair pathway dependencies

2020-10-18

Abstract excerpt

<h4>ABSTRACT</h4> DNA repair deficiencies have become an increasingly promising target for novel therapeutics within the realm of clinical oncology. Recently, several inhibitors of Poly(ADP-ribose) Polymerases (PARPs) have received approval for the treatment of cancers primarily with deleterious mutations in the homologous recombination (HR) proteins, BRCA1 and BRCA2. Despite numerous clinical trials which have b...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 56ab1b0f-7c17-5476-9c9e-6e94fa032504
DOI: 10.1101/2020.10.18.333070

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CRISPR screening identifies novel PARP inhibitor classification based on distinct base excision repair pathway dependenciesDOI 10.1101/2020.10.18.333070Read

CRISPR screens guide the way for PARP and ATR inhibitor biomarker discoverySemantic proximity Read

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibitionSemantic proximity Read

Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated CancerSemantic proximity Read

Recent advancements in PARP inhibitors-based targeted cancer therapySemantic proximity Read

Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP InhibitionSemantic proximity Read

PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistanceSemantic proximity Read

PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant CancersSemantic proximity Read

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitorsSemantic proximity Read

Predictive biomarkers for cancer therapy with PARP inhibitors.Semantic proximity Read

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerSemantic proximity Read

Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.Semantic proximity Read

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage responseSemantic proximity Read